Methods and compositions for treatment of a genetic condition
Methods and compositions comprising single guide RNAs targeted to an endogenous mammalian β globin gene (HBB), gamma globin gene (HBG1), B-cell lymphoma/leukemia 11A (BCL11A) gene, Kruppel-like factor 1 (KLF1) gene, CCR5 gene, CXCR4 gene, PPP1R12C (AAVS1) gene, hypoxanthine phosphoribosyltransferase (HPRT) gene, albumin gene, Factor VIII gene, Factor IX gene, Leucine-rich repeat kinase 2 (LRRK2) gene, Hungtingin (Htt) gene, rhodopsin (RHO) gene, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, surfactant protein B gene (SFTPB), T-cell receptor alpha (TRAC) gene, T-cell receptor beta (TRBC) gene, programmed cell death 1 (PD1) gene, Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) gene, human leukocyte antigen (HLA) A gene, a LMP7 gene, a Transporter associated with Antigen Processing (TAP) gene, tapasin gene (TAPBP), a class II major histocompatibility complex transactivator (CIITA) gene, a dystrophin gene (DMD), a glucocorticoid receptor gene (GR), IL2RG gene or RFX5 for genetic alteration of cells are provided.
1. A single-guide RNA that binds to an endogenous gene selected from the group consisting of mammalian β globin gene (HBB), a gamma globin gene (HBG1), a B-cell lymphoma/leukemia 11A (BCL11A) gene, a Kruppel-like factor 1 (KLF1) gene, an hypoxanthine phosphoribosyltransferase (HPRT) gene, an albumin gene, a Factor IX gene, a Leucine-rich repeat kinase 2 (LRRK2) gene, a Hungtingin (Htt) gene, a rhodopsin (RHO) gene, a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, a T-cell receptor alpha (TRAC) gene, a T-cell receptor beta (TRBC) gene, a programmed cell death 1 (PD1) gene, a Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) gene, an human leukocyte antigen (HLA) A gene, an HLA B gene, an HLA C gene, an HLA-DPA gene, an HLA DRA gene, a Transporter associated with Antigen Processing (TAP) 1 gene, a TAP2 gene, a tapasin gene (TAPBP), a class II major histocompatibility complex transactivator (CIITA) gene, and an RFX5 gene, wherein the single-guide RNA is selected from the group consisting of SEQ ID NOs: 149-158 and 167-215.
2. A system comprising the single-guide RNA of claim 1 and a functional domain that associates with the single-guide RNA.
3. The system of claim 2 , wherein the functional domain is selected from the group consisting of a transcriptional activation domain, a transcriptional repression domain and a nuclease domain.
4. The system of claim 3 , wherein the functional domain is a Type IIS restriction enzyme nuclease domain or a Cas protein.
5. The system of claim 3 , wherein the functional domain is a transcriptional activation domain.
6. The system of claim 3 , wherein the functional domain is a transcriptional repression domain.
7. The system of claim 4 , wherein the Cas protein comprises one more nuclease cleavage domains.
8. A mammalian cell comprising the system of claim 2 .
9. The mammalian cell of claim 8 , wherein the mammalian cell is a stem cell.
10. A method of modifying the expression of an endogenous gene in a cell, the method comprising the steps of: administering to the cell a first nucleic acid molecule comprising a single guide RNA according to claim 1 that recognizes a target site in the endogenous gene and a second nucleic acid molecule that encodes a functional domain, wherein the functional domain associates with the single guide RNA on the target site, thereby modifying the expression of the endogenous gene.
11. The method of claim 10 , wherein the functional domain is selected from the group consisting of a transcriptional activation domain, a transcriptional repression domain and a nuclease domain.
12. The method of claim 11 , wherein the functional domain is a TypeIIS restriction enzyme nuclease domain or a Cas protein.
13. The method of claim 11 , wherein the functional domain is a transcriptional activation domain and expression of the endogenous gene is increased.
14. The method of claim 11 , wherein the functional domain is a transcriptional repression domain and expression of the endogenous gene is inhibited.
15. The method of claim 11 , wherein the functional domain is a nuclease and the endogenous gene is cleaved.
16. The method of claim 15 , where the nuclease domain is comprised by the Cas protein.
17. The method of claim 16 , where the Cas protein comprises one more nuclease cleavage domains.
18. The method of claim 10 , wherein the cell is a mammalian cell.
19. The method of claim 18 , wherein the mammalian cell is a stem cell.